Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
FMR LLC, a ten percent owner of Beam Therapeutics Inc., reported indirect open-market sales of Beam common stock through F-Prime Capital Partners Healthcare Fund V LP.
The entity sold 33,372 shares on June 25, 2026 at a weighted average price of $35.12 per share, and 251,488 shares on June 26, 2026 at a weighted average price of $35.26 per share, for total reported sales of 284,860 shares. After these transactions, one reported indirect holding shows 854,583 shares remaining for the F-Prime Capital Partners Healthcare Fund V LP position. Additional indirect holdings include 841,231 shares held by persons and entities whose shares are subject to reporting by FMR LLC and 14 shares held by FMR Capital, Inc.
Beam Therapeutics Inc. president Giuseppe Ciaramella reported exercising stock options to acquire a total of 35,505 shares of common stock on June 17, 2026. These transactions were coded “M,” indicating exercises or conversions of derivative securities rather than open‑market purchases or sales.
The options exercised carried strike prices of $1.03 and $0.67 per share. The underlying options had vesting schedules beginning February 26, 2018, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, reflecting long-term equity compensation.
Beam Therapeutics Inc. reported results from its 2026 annual meeting of stockholders held on June 3, 2026. Stockholders elected Class III directors John Evans, John Maraganore, Ph.D., and Christi Shaw to serve until the 2029 annual meeting, with each nominee receiving over 64.8 million votes in favor and substantial broker non-votes.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 85.75 million votes for and minimal opposition. In addition, they approved, on an advisory basis, the compensation of the company’s named executive officers, with approximately 71.5 million votes for and relatively low opposition and abstentions.
Beam Therapeutics director Christi Shaw received a grant of stock options, giving the right to buy 19,676 shares of Common Stock at an exercise price of $29.55 per share. The options vest in full on the earlier of one year from grant or immediately before the next annual stockholders' meeting, contingent on continued board service, and expire on June 3, 2036. After this grant, 19,676 derivative securities are reported as held directly.
Beam Therapeutics Inc. director Kathleen E. Walsh received a grant of stock options covering 19,676 shares of Common Stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
According to the footnote, the option vests in full on the earlier of the first anniversary of the grant date or immediately before next year's annual stockholder meeting, as long as Walsh continues serving on the board through the vesting date. After this grant, she holds options for 19,676 shares directly.
Beam Therapeutics Inc. director John Maraganore received a grant of stock options covering 19,676 shares of common stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
According to the award terms, the option vests in full on the earlier of the first anniversary of the grant date or immediately prior to next year’s annual meeting of stockholders, as long as he continues serving on the board. Following this grant, he holds 19,676 stock options directly and the filing reports no open‑market purchases or sales.
Beam Therapeutics Inc. director Mark Fishman received a grant of stock options covering 19,676 shares of common stock. The options have an exercise price of $29.55 per share and were awarded as compensation, not purchased in the open market.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, as long as Fishman continues serving on the board through that date. The options expire on June 3, 2036, giving him long-term potential ownership if exercised.
Beam Therapeutics Inc. director Guindo Chirfi received a stock option grant as equity compensation. The award covers 19,676 shares of Beam common stock at an exercise price of $29.55 per share, expiring on June 3, 2036. The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual meeting of stockholders, as long as Chirfi continues serving on the board through the vesting date. This is a non-cash, routine director compensation grant and not an open-market share purchase or sale.
Beam Therapeutics Inc. director Graham K. Cooper reported receiving a grant of stock options to acquire 19,676 shares of common stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, provided he continues serving on the board through the vesting date. Following this grant, he holds 19,676 derivative securities directly.
Beam Therapeutics Inc. reports Q1 2026 results with license and collaboration revenue of $31.7 million, up from $7.5 million a year earlier, narrowing operating loss. Research and development spending reached $104.5 million, while net loss improved to $94.3 million, or $0.91 per share.
Beam ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities and drew an initial $100 million from a new credit facility maturing in 2033. Management believes this liquidity can fund operations for at least 12 months as the company advances multiple base-editing programs, including risto-cel for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency.